Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-12
2005-04-12
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S473000, C549S065000, C549S479000
Reexamination Certificate
active
06878742
ABSTRACT:
Compounds of Formula (I),wherein R1, R2, R3, R4, R5, R6, T, W, X, Y and Z are as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs thereof. Methods of using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are described
REFERENCES:
patent: 5464853 (1995-11-01), Chan et al.
patent: 5514691 (1996-05-01), Chan et al.
patent: 5571821 (1996-11-01), Chan et al.
patent: 5591761 (1997-01-01), Chan et al.
patent: 5593846 (1997-01-01), Schenk
patent: 5594021 (1997-01-01), Chan et al.
patent: 5624937 (1997-04-01), Reel
patent: 5703129 (1997-12-01), Felsenstein
patent: 5852007 (1998-12-01), Chatterjee
patent: 5981168 (1999-11-01), Reiner
patent: 6248775 (2001-06-01), Vazquez
patent: 6376523 (2002-04-01), Chan et al.
patent: 6566536 (2003-05-01), Muller et al.
patent: 6610734 (2003-08-01), Kreft et al.
patent: 20020183361 (2002-12-01), Kreft et al.
patent: 20030013892 (2003-01-01), Resnick et al.
patent: 510700 (1992-10-01), None
patent: 652009 (1995-05-01), None
patent: 1088821 (2001-04-01), None
patent: 1172361 (2002-01-01), None
patent: 5-148233 (1993-06-01), None
patent: 11-343279 (1999-12-01), None
patent: WO9529904 (1995-11-01), None
patent: WO9803166 (1998-01-01), None
patent: WO9822104 (1998-05-01), None
patent: WO9822493 (1998-05-01), None
patent: WO0009107 (2000-02-01), None
patent: WO0050391 (2000-08-01), None
patent: WO0123379 (2001-04-01), None
patent: WO0127091 (2001-04-01), None
patent: WO0127108 (2001-04-01), None
patent: WO-03050062 (2003-06-01), None
patent: WO-03050063 (2003-06-01), None
patent: WO-03103660 (2003-12-01), None
A. Larner et al, “Review—Central & Peripheral Nervous Systems—Alzheimer's Disease: Towards Therapeutic Manipulation of the Amyloid Precursor Protein and Amyloid β-peptides”, Exp. Opin. Ther. Patents, 7(10):1115-1127 (1997).
C. Moore et al, “Inhibition of β-amyloid Formation as a Therapeutic Strategy”, Exp. Opin. Ther. Patents, 9(2):135-146 (1999).
V. John et al, “Alzheimer's Disease: Recent Advances on the Amyloid Hypothesis”, in Annual Reports in Medicinal Chemistry, Chapter 2, pp. 11-20 (1997).
G. Rishton et al, “Fenchylamine Sulfonamide Inhibitors of Amyloid β Peptide Production by the γ-Secretase Proteolytic Pathway: Potential Small-Molecule Therapeutic Agents for the Treatment of Alzheimer's Disease”, J. Med. Chem., 43(12):2297-2299 (Jun. 15, 2000).
B. Testa et al, “Prodrugs Revisited: The “Ad Hoc” Approach as a Complement to Ligand Design”, Medicinal Research Reviews, 16(3):233-241 (May, 1996).
D. Skovronsky et al, “β-Secretase Revealed: Starting Gate for Race to Novel Therapies for Alzheimer's Disease”, TIPS, 21:161-163 (May, 2000).
A. Ghosh et al, “Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase)”, J. Am. Chem. Soc., 122:3522-3523 (2000).
W. Esler et al, “Transition-State Analogue Inhibitors of γ-Secretase Bind Directly to Presenilin-1”, Nature Cell Biology, 2:428-434 (Jul., 2000).
Y-M. Li et al, “Photoactivated γ-Secretase Inhibitors Directed to the Active Site Covalently Label Presenilin 1”, Nature, 405:689-694 (Jun., 2000).
M. Wolfe et al, “A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer's γ-Secretase Activity”, J. Med. Chem., 41:6-9 (Jan. 1, 1998).
S. Sinha et al, “Purification and Cloning of Amyloid Precursor Protein β-Secretase from Human Brain”, Nature, 402:537-540 (Dec., 1999).
A. Goate, “Monogenetic Determinants of Alzheimer's Disease: APP Mutations”, CMLS Cell. Mol. Life Sci., 54:897-901 (Sep., 1998).
M. Sabbagh et al, “β-Amyloid and Treatment Opportunities for Alzheimer's Disease”, Alzheimer's Disease Review, 3:1-19 (1997).
C. Augelli-Szafran et al, β-Amyloid as a Target for Alzheimer's Disease Therapy, in Annual Reports in Medicinal Chemistry, Chapter 3, pp. 21-30 (1999).
J-C. Dodart et al, “The β-Amyloid Precursor Protein and its Derivatives: from Biology to Learning and Memory Processes”, Reviews in the Neurosciences, 11(2-3):75-93 (2000).
D. Small et al, “Alzheimer's Disease and the Amyloid β Protein: What is the Role of Amyloid?”, Journal of Neurochemistry, 73(2):443-449 (Aug., 1999).
J. Näslund et al, “Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline”, JAMA, 283(12):1571-1577 (Mar., 2000).
Q-X. Li et al, “The Amyloid Precursor Protein of Alzheimer Disease in Human Brain and Blood”, Journal of Leukocyte Biology, 66:567-574 (Oct., 1999).
S. Wagner et al, “Modulation of Amyloid β Protein Precursor Processing as a Means of Retarding Progression of Alzheimer's Disease”, The Journal of Clinical Investigation, 104(10):1329-1332 (Nov., 1999).
Y. Han et al, “Total Asymmetric Synthesis of Highly Constrained Amino Acids Isopropyl-2', 6'-Dimethyl-Tyrosines”, Tetrahedron Letters, 38(29):5135-5138 (1997).
M. Findeis et al, “Modified-Peptide Inhibitors of Amyloid β-Peptide Polymerization”, Biochemistry, 38(21):6791-6800 (May, 1999).
Wermuth et al., “Molecular variations based on isosteric replacements”, Prac. Med. Chem., Academic Press, pp. 203-237 (Feb. 1996).
Casebier David S.
Cole Derek C.
Diamantidis George
Kreft Anthony F.
Kubrak Dennis M.
ArQule, Inc.
Howson and Howson
Lambkin Deborah C.
Wyeth
LandOfFree
Heterocyclic sulfonamide inhibitors of beta amyloid production does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic sulfonamide inhibitors of beta amyloid production, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic sulfonamide inhibitors of beta amyloid production will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3424004